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A B S T R A C T
Purpose: Insulin/insulin receptor (INSR) signaling plays diverse roles in the central nervous system,
including regulation of blood glucose, synaptic plasticity, dendritic growth, modulation of electrophys-
iological activity, proliferation of astrocytes and neuronal apoptosis. Interestingly, many of these and/or
related processes represent biological mechanisms associated with temporal lobe epilepsy (TLE). Thus,
insulin signaling may play a role in the development of TLE and its therapeutic responses. We
hypothesized that functional polymorphisms in the insulin pathway genes INSR, insulin receptor
substrate 1 (IRS1), and IRS2 may be associated with the therapeutic responses of TLE. Therefore, in this
study we analyzed the association of three single nucleotide polymorphisms (SNPs) showing a risk for
TLE drug resistance using a hospital-based case–control design.
Method: Two hundred and one patients with refractory TLE and one hundred and seventy-ﬁve drug-
responsive TLE patients were recruited for the study. Polymerase chain reaction–restriction fragment
length polymorphism was used to detect the genotypes of INSR His1085His, IRS1 G972R and IRS2
1057G/A.
Results: No signiﬁcant differences between refractory and drug-responsive TLE patients were observed
for the IRS1 G972R and IRS2 1057G/A polymorphisms (P > 0.05), but a signiﬁcant association was found
for the INSR His1085His polymorphism for both genotypes (P = 0.035) and alleles (P = 0.011). IRS2
1057G/A combined with the INSR His1085His polymorphism increased the odds ratio of drug resistance
in TLE (P = 0.011, OR = 2.263, 95% CI: 1.208–4.239).
Conclusion: These results suggest that a genetic variation in the insulin signaling pathway genes may
affect the therapeutic response of TLE.
 2014 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Temporal lobe epilepsy (TLE) is the most common heteroge-
neous epilepsy syndrome, with both environmental and genetic* Corresponding author at: Neurology Department, Provincial Hospital Afﬁliated
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the phenotypic features of TLE, including responses to anti-
epileptic drugs.
Insulin/insulin receptor (INSR) signaling plays diverse roles in
the central nervous system (CNS), including regulation of blood
glucose, synaptic plasticity, dendritic growth, modulation of
electrophysiological activity, proliferation of astrocytes and
neuronal apoptosis.1–3 Many of these and/or related processes,
including neuronal loss, energy metabolism dysfunctions, neuro-
genesis and synaptic reorganization also represent mechanisms
associated with TLE.4 A further link between INSR and epilepsy has
been revealed from a recent report showing that IR expression is
increased in the anterior temporal neocortex of patients withserved.
F. Che et al. / Seizure 25 (2015) 178–180 179intractable epilepsy.5 Therefore, insulin and/or INSR signaling may
play a role in the etiology of TLE and its therapeutic response. We
hypothesized that functional polymorphisms in the insulin
pathway genes INSR, insulin receptor substrate 1 (IRS1), and
IRS2 may be associated with the therapeutic response of TLE. The
aim of the current study was to investigate the association of INSR
H1085H C>T, IRS1 G972R and IRS2 1057G/A polymorphisms as
related with refractory TLE.
2. Methods
2.1. Patients
The study was performed between July 2012 and April 2014
with the approval of the ethics committee at Shandong
University. All subjects voluntarily participated in this study.
Written informed consent was obtained from all subjects
following a complete description of the study. The study
consisted of 201 patients with drug-resistant TLE and 175
patients with drug-responsive TLE. All TLE subjects who had
been receiving antiepileptic drug treatment for at least two years
were diagnosed and recruited by physicians in the Neurology
Department of Linyi People’s Hospital. The criteria for TLE
diagnosis were based upon the 1989 ILAE’s clinical classiﬁcation.
Among all the patients, refractory TLE was deﬁned as four or
more seizures over a 4-week period during the previous year,
when receiving two or more appropriate and sufﬁcient doses of
antiepileptic drugs. Non-refractory epilepsy was deﬁned as the
absence of seizures for at least a one-year period. Seizure
frequency was self-reported by the patients and their family
members, and averaged for each month over the previous 6
month period. Venous blood samples (5 mL) were taken for DNA
extraction and genotyping. Subject information and genotype
data were identiﬁed by a code to ensure that the genotyping was
performed blind.
2.2. Genotyping
Genomic DNA was extracted from peripheral blood leukocytes
using standard methods. All polymorphisms were genotyped by
the polymerase chain reaction (PCR)-restriction fragment length
polymorphism method. Genotyping of the INSR H1085H C>T, IRS1
G972R and IRS2 1057G/A was conducted by polymerase chain
reaction (PCR), followed by the appropriate restriction enzyme
digestion (PCR–restriction fragment length polymorphism [RFLP]).
Primer sequences and conditions for PCR–RFLP analyses areTable 1
Genotypic and allelic frequencies in drug resistant group and drug responsive group.
Gene/SNP Genotype/allele Drug-resistant (n = 201) (%) 
INSR H1085H TT 24 (11.9%) 
CT 97 (48.3%) 
CC 80 (39.8%) 
T 145 (36.1%) 
C 257 (63.9%) 
IRS1 Gly972Arg AA 1 (0.5%) 
GA 15 (7.5%) 
GG 185 (92.0%) 
A 17 (4.2%) 
G 385 (95.8%) 
IRS2 Gly1057Asp AA 20 (10.0%) 
GA 72 (35.8%) 
GG 109 (54.2%) 
A 112 (27.9%) 
G 290 (72.1%) 
Data presented as number of subject (percentage).presented in Supplementary Table S1. DNA fragments were
electrophoresed in 3% agarose gels.
2.3. Statistical analysis
Deviation from the Hardy–Weinberg equilibrium (HWE) and
differences in allele and genotype distributions were assessed
using the x2 test or Fisher’s exact test where appropriate.
Quantitative traits were accessed by t-test. The effect of gene–
gene interaction was tested using binary logistic regression
analysis. The odds ratio (OR) was calculated with a 95% conﬁdence
interval (95% CI). All tests were performed at a level of signiﬁcance
of 5% (P < 0.05).
3. Results
Demographic and clinical variables of the subjects are
summarized in Supplementary Table S2. Refractory and drug-
responsive TLE subjects show signiﬁcant differences with respect
to the age at seizure onset, duration of epilepsy, and hippocampal
sclerosis rates.
Genotypic and allelic distributions for INSR H1085H C>T, IRS1
G972R and IRS2 1057G/A polymorphisms are summarized in
Table 1. Distributions of genotypic frequencies for the three
polymorphisms were in the Hardy–Weinberg equilibrium. No
signiﬁcant differences were detected in genotypic or allelic
frequencies at IRS1 G972R and IRS2 1057G/A between refractory
and drug-responsive TLE subjects. The genotypic distribution of
the His1085His polymorphism differed signiﬁcantly (P = 0.035)
between the refractory and drug-responsive TLE groups. Further
analyses showed that the His1085His ‘‘T’’ allele frequency
accumulated in refractory TLE subjects (36.1%) to a greater extent
as compared with drug-responsive TLE subjects (27.4%), suggest-
ing a signiﬁcant involvement of the His1085His ‘‘T’’ allele as a
probable independent risk factor for refractory TLE (P = 0.011,
OR = 1.493, 95% CI: 1.094–2.037).
Table 2 shows the gene–gene interaction of INSR H1085H C>T,
IRS1 G972R and IRS2 1057G/A in TLE. To assess all possible gene
interactions, nine possible combinations as shown in the table
were chosen for analyses. Logistic regression analysis was
performed as a means to determine whether the presence or
absence of either variant allele of INSR H1085H C>T, IRS1 G972R
and IRS2 1057G/A alone or in combinations could alter the odds
ratio of drug resistance. With combinations of INSR H1085H C>T
and IRS2 1057G/A (INSR CT + TT and IRS2 GA + AA were present),
we found odds ratios of 2.263 fold. These data were also analyzedDrug-responsive (n = 175) (%) P OR (95% CI)
13 (7.4%) 0.035
70 (40%)
92 (52.6%)
96 (27.4%) 0.011 1.493 (1.094–2.037)
254 (72.6%)
0 (0%) 0.628
12 (6.9%)
163 (93.1%)
12 (3.4%) 0.705 1.244 (0.586–2.642)
338 (96.6%)
12 (6.9%) 0.408
58 (33.1%)
105 (60%)
82 (23.4%) 0.166 1.262 (0.908–1.755)
268 (76.6%)
Table 2
Regression analysis of genotypic interaction of INSR H1085H C>T, IRS1 G972R and IRS2 1057G/A between drug resistant group and drug responsive group.
INSR (CT + TT) IRS2 (GA + AA) IRS1 (GA + AA) Drug resistant Drug responsive P value OR (95% CI)
Absent Absent Absent 40 (19.9%) 47 (26.9%) – 1.0 (reference)
Absent Absent Present 4 (2.0%) 3 (1.7%) 0.572 1.567 (0.331–7.420)
Absent Present Absent 39 (19.4%) 38 (21.7%) 0.804 1.082 (0.580–2.019)
Absent Present Present 1 (0.5%) 4 (2.3%) 0.282 0.294 (0.032–2.736)
Present Absent Absent 58 (28.9%) 51 (29.1%) 0.315 1.336 (0.759–2.351)
Present Absent Present 7 (3.5%) 4 (2.3%) 0.277 2.056 (0.561–7.536)
Present Present Absent 48 (23.8%) 27 (15.4%) 0.011 2.263 (1.208–4.239)
Present Present Present 4 (2.0%) 1 (0.6%) 0.174 4.700 (0.505–43.755)
Data presented as number of subject (percentage).
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between the adjusted and unadjusted data, which failed to differ
signiﬁcantly (data not shown).
4. Discussion
Exon 17 encodes the partial tyrosine kinase domain containing
the ATP binding site of INSR, which is a key factor in
phosphorylation during autophosphorylation responses.6 IRS1
Gly972Arg and the IRS2 Gly1057Asp SNPs were selected for
analysis due to their putative effects on p85 and GRB2 binding,
which result in impaired signaling.7 Our results suggest that the
His1085His ‘‘T’’ allele and the CT + TT genotypes of INSR may be
associated with refractory TLE susceptibility. The His1085His ‘‘T’’
allele frequency was signiﬁcantly higher in patients with
refractory TLE than in drug-responsive TLE subjects. Moreover,
an analysis of gene–gene interactions of the INSR H1085H C>T and
IRS2 1057G/A polymorphisms provides further support that the
His1085His ‘‘T’’ allele may contribute to the etiology of refractory
TLE. Taken together, these results suggest that a speciﬁc set of
polymorphic genes in the insulin signaling pathway have the
potential to inﬂuence therapeutic responses in TLE.
The possible relationship between insulin/INSR signaling and
TLE is also supported by previous experimental data. For example,
INSRs are widely expressed in the brain and insulin-bound insulin
receptor activates IRS1 and IRS2, which can then bind to the p85
subunit of the phosphatidylinositol (PI)-3 kinase and activate the
serine kinase PKB/Akt pathway to regulate apoptosis and glucose
metabolism. Moreover, there are data which suggest that glycemic
modulation can alter seizure thresholds and reduce the extent of
seizure-induced cell death following kainate administration8; and,
insulin has been shown to inhibit hippocampal epileptiform-like
activity.9 Emerging evidence suggests an important role for insulin
signaling in synaptic plasticity by modulating the surface
expression of N-methyl-D-aspartate, a-amino-3-hydroxy-5-meth-
yl-4-isoxazolepropionic acid, and g-aminobutyric acid (GABA) A
receptors,1,9,10 and modulating glutamatergic10 and GABAergic1
synaptic transmission in the hippocampus. As synaptic plasticity
has been linked with neural network reorganization,11 the
recurrence of seizures may cause abnormal network reorganiza-
tion, thus contributing to TLE.12
In conclusion, our results suggest INSR CT or TT genotype
carriers have an increased risk for developing refractory TLE. The
risk effect was even stronger among carriers with both the INSR (CT
or TT) and the IRS2 (GA or AA) genotypes. Further studies withother independent samples sets will be required to conﬁrm the
ﬁndings of this report.
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